Affordable Access

deepdyve-link
Publisher Website

Targeting Tumor Vasculature Using Adeno-Associated Virus Phage Vectors Coding Tumor Necrosis Factor-α

Authors
  • Yuan, Ziqiang
  • Pastoriza, Jessica
  • Quinn, Thomas
  • Libutti, Steven K.
Type
Book
Journal
Gene Therapy of Cancer
Publication Date
Jan 01, 2014
Pages
19–33
Identifiers
DOI: 10.1016/B978-0-12-394295-1.00002-0
ISBN: 978-0-12-394295-1
Source
Elsevier
Keywords
License
Unknown

Abstract

An advantage of targeted gene therapy is the potential for effectively delivering anti-vascular and antitumor therapy directly to the site of the tumor, thus maximizing therapeutic efficacy and minimizing toxicity. The use of a vector capable of directed cell transduction can result in the sustained expression of the therapeutic agent. This chapter reviews the current status of vector strategies, targeted gene therapy with tumor-specific promoter and antibody and peptide conjugation, and outlines the challenges faced for the next-generation of gene transfer technology. Furthermore, it summarizes the results of preclinical anti-angiogenic gene therapy investigations, which utilize novel targeted tumor necrosis factor-α treatment, and discusses potential clinical applications of this treatment strategy.

Report this publication

Statistics

Seen <100 times